Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NAMPT | P43490 | 6/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22275143 | 0.83 | LMNA (0.59) | TSHRMAPK1ALDH1A1LMNAHIF1A | |
| SCHEMBL13701744 | 0.81 | ALDH1A1 (0.64) | TSHRMAPK1ALDH1A1LMNAHIF1A | |
| SCHEMBL12977867 | 0.81 | ALDH1A1 (0.60) | TSHRMAPK1ALDH1A1LMNAHIF1A | |
| SCHEMBL30533390 | 0.80 | LMNA (0.81) | TSHRMAPK1ALDH1A1LMNAHIF1A | |
| SCHEMBL12077633 | 0.79 | NAMPT (0.82) | MAPK1ALDH1A1LMNANPC1RAB9A | |
| SCHEMBL16881794 | 0.79 | NPC1 (0.75) | TSHRALDH1A1LMNAHIF1ANPC1 | |
| SCHEMBL14438266 | 0.78 | NPC1 (0.55) | TSHRMAPK1ALDH1A1LMNANPC1 | |
| SCHEMBL1078986 | 0.77 | NAMPT (0.78) | MAPK1LMNANAMPTMAPTL3MBTL1 | |
| SCHEMBL996338 | 0.77 | TSHR (0.67) | TSHRMAPK1ALDH1A1LMNANPC1 | |
| SCHEMBL31661935 | 0.77 | BRAF (0.79) | ALDH1A1LMNAHIF1ANPC1NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | TSHR 3976/4885MAPK1 3943/4885ALDH1A1 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.